The incidence of anal cancer is rising in the United States, and most anal squamous cell carcinoma (SCCA) is associated with high-risk human papillomavirus subtypes.

Not all patients with SCCA have the typical risk factors for development of the disease.

SCCA rarely metastasizes, but most common sites are liver, lung, extrapelvic lymph nodes, peritoneum, and bone.

This is a case of a patient with SCCA that metastasized to his sigmoid colon without evidence of other distant disease.

Pembrolizumab is an option for patients with advanced SCCA that is not amenable to chemotherapy or surgical resection. It has also been recently approved for tumors with high tumor mutation burden.

在美国，肛门癌的发病率正在上升，大多数肛门鳞状细胞癌 (SCCA) 与高危人乳头瘤病毒亚型有关。

并非所有 SCCA 患者都具有该疾病发展的典型危险因素。

SCCA 很少转移，但最常见的部位是肝、肺、盆腔外淋巴结、腹膜和骨。

这是一例 SCCA 患者在没有其他远处疾病证据的情况下转移至乙状结肠的病例。

对于不适合化疗或手术切除的晚期 SCCA 患者，派姆单抗是一种选择。它最近也被批准用于具有高肿瘤突变负荷的肿瘤。